Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children

Acute Upper Respiratory Tract Infections Clinical Trial

Official title:

Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01843842
• Other study ID #: MMH-ER-007
• Status: Completed
• Phase: Phase 3
• Start date: April 2013
• Est. completion date: March 2015

Study information

• Verified date: November 2018
• Source: Materia Medica Holding
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is:

• to assess safety of the liquid dosage form of Ergoferon for treatment of acute upper respiratory tract infections in children;

• to assess clinical efficacy of the liquid dosage form of Ergoferon for treatment acute upper respiratory tract infections in children.

Description:

The overall duration of a patient's participation in the trial is 6 days (screening/randomization, therapy onset - day 1; study therapy period - 5 days; follow-up period-1 day).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 306
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 18 Years

Eligibility

Inclusion Criteria:

1. Patients of both sexes aged over 3 years and under 18 years.

2. Patients who consulted a doctor within 24 hours after the onset of acute respiratory infection (body temperature no less than 38.0°C when visiting a doctor + intensity of symptoms = 4 scores (presence of at least 1 general symptom = 2 scores and 1 nasal/ throat/ chest symptom = 2 scores or greater number of symptoms with the intensity=1 score) during seasonal morbidity.

3. The possibility to start therapy within 24 hours after the onset of the first symptoms of acute respiratory infection.

4. Usage of contraceptive methods by sexually active teenagers of both sexes during the trial and within 30 days after ending of the participation in the trial.

5. Availability of information sheet (Informed Consent form) for parents/adopters of patient for participation in the clinical trial, Version 2.1 or Version 2.2, signed by one parent/adopter of patient. For patients over 14 years - availability of information sheet (Informed Consent form) for participation in the clinical trial, Version 2.1 or Version 2.2, signed by a patient and one parent/adopter of patient.

Exclusion Criteria:

1. Suspected bacterial infection or presence of a severe disease requiring use of antibacterial drugs (including sulfanilamides).

2. Suspected initial manifestations of diseases that have symptoms similar to acute respiratory infection (other infectious diseases, influenza-like syndrome at the onset of systemic connective tissue disorders, oncohematology and other pathology).

3. Medical history of primary and secondary immune deficiency: a) lymphoid system immunodeficiency (T-cell and /or B-cell immunity chain, immunodeficiency with predominant antibody deficiency); b) phagocyte deficiency; c) complement factors deficiency; d ) combined immunodeficiency including AIDS induced by HIV infection; toxic, autoimmune, infectious, radial panleukopenia syndrome; general lymphocytopenia syndrome; syndrome of lymphocyte polyclonal activation; postsplenectomia syndrome; congenital asplenia; syndrome of immune complexes pathology associated with infectious, allergic and autoimmune diseases.

4. Medical history of sarcoidosis.

5. Oncological diseases.

6. Exacebration or decompensation of chronic diseases affecting the patient's ability to participate in the clinical trial.

7. Medical history of polyvalent allergy.

8. Allergy/ intolerance to any of the components of medications used in the treatment.

9. Impaired glucose tolerance, diabetes mellitus.

10. Hereditary fructose intolerance (as the study drug contains maltitol).

11. Intake of medicines listed in the section "Prohibited concomitant treatment" for 1 month prior to the inclusion in the trial.

12. Pregnancy, unwillingness of sexually active female patients to use of contraceptive methods during the study.

13. Drug addiction, alcohol usage in the amount 2 units of alcohol per day on the part of patient's parents/adopters.

14. Mental disorders of patient or of patient's parents/adopters.

15. Patient's parents/ adopters, who from investigator's point of view, will fail to comply with the observation requirements of the trial or with the intake regimen of the investigated medicines.

16. Participation in other clinical trials in the course of 3 months prior to the inclusion in the trial.

17. Patient's parent/adopter is related to the research personnel of the investigative site, who are directly involved in the trial or are the immediate relative of the researcher. The immediate relatives includes husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.

18. Patient's parent/adopter works for OOO "NPF "Materia Medica Holding" (i.e. is the company's employee, temporary contract worker or appointed official responsible for the carrying out the research) or the immediate relative.

Related Conditions & MeSH terms

• Acute Upper Respiratory Tract Infections
• Communicable Diseases
• Infection
• Respiratory Tract Infections

Intervention

Drug:
• Ergoferon
Safety and Efficiency of liquid dosage form
• Placebo
Safety and Efficiency of liquid dosage form

Locations

Country	Name	City	State
Russian Federation	Municipal Institution "Child Health City Hospital ?11"	Ekaterinburg
Russian Federation	State Educational Institution of Higher Professional Education "Moscow State Medical Academy named after I.M. Sechenov"	Moscow
Russian Federation	State Budgetary Educational Institution of Higher Professional Education Novosibirsk State Medical University of Ministry of Health of Russian Federation	Novosibirsk
Russian Federation	Municipal Health Care Institution "City Child Health Clinical Polyclinic ?5"	Perm
Russian Federation	St. Peterburg State Health Care Institution "Child Health City Hospital ?45 of the Nevsky Region"	St. Peterburg
Russian Federation	St. Petersburg State Budgetary Health Care Institution "?ity Polyclinic ?44"	St. Petersburg
Russian Federation	State Budgetary Educational Institution of Higher Professional Education "St. Petersburg State Pediatric Medical Academy" of Ministry of Health of Russian Federation	St. Petersburg
Russian Federation	State Budgetary Health Care Institution "?ity Child Health Polyclinic ?44"	St. Petersburg
Russian Federation	State Health Care Institution "Child Health City Hospital ?22"	St. Petersburg
Russian Federation	Limited Liability Company "Alliance Biomedical-Russian group"	St.Petersburg
Russian Federation	State Budgetary Educational Institution of Higher Professional Education " Yaroslavl State Medical Academy" of Ministry of Health	Yaroslavl

Sponsors (1)

Lead Sponsor	Collaborator
Materia Medica Holding

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Patients With Recovery/Improvement in Health on Days 2, 3 and 4 of Observation (Based on Patient Diary Data)	Based on the data mentioned in a patient's diary	On day 2, 3 and 4 of observation
Secondary	Dynamics of Fever (Changes in Body Temperature on 2, 3, 4, 5 Days of Observation in Comparison With the Baseline)		baseline and days 2, 3, 4 and 5 of observation
Secondary	Percentage of Patients With Normal Body Temperature (=37.0º?)	Axillary temperature (morning and evening) decline to or below 37.0 º?	On day 2, 3, 4, 5 of observation
Secondary	Severity of Clinical Manifestations of Acute Respiratory Infection (ARI) by Total Symptom Score on Day 3 of Observation (Based on the Results of Pediatrician's Examination) and on Days 2, 3, 4 and 5 of Observation (Based on Patient Diary Data)	The Total Symptom Score (TSS) was based on the severity of each of acute respiratory infection (ARI) symptom.; The TSS includes 13 symptoms: Body temperature / fever, Non-specific ARI symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), Nasal/Throat/Chest symptoms (Runny nose, Nasal congestion, Sneezing, Sore throat, Hoarseness, Cough, Chest pain/Tightness of the chest).; The severity of Non-specific and Nasal/Throat/Chest symptom was scored on a symptom severity scale (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms). The Fever was scored on a symptom severity scale 0 = no symptom (=37,30?); 1 = mild symptom (37,4-38,00?); 2 = moderate symptom (38,1-39,00); 3 = severe symptom (=39,10?).; Minimum score=0; maximum score=39. The severity of ARI symptoms was recorded: 1) by the doctors on the case record form on Day 3; 2) by one of the patient's parents/adopter on a diary card twice a day (morning and evening) on Days 2-5.	on Days 2, 3, 4, 5 of Observation
Secondary	Duration of Acute Respiratory Infection Symptoms (Fever, Non-specific Symptoms and Nasal/ Throat/ Chest Symptoms) Based on Patient Diary Data	Acute respiratory infection (ARI) symptoms include 13 symptoms: Body temperature / fever, Non-specific ARI symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), Nasal/Throat/Chest symptoms (Runny nose, Nasal congestion, Sneezing, Sore throat, Hoarseness, Cough, Chest pain/Tightness of the chest).; The ARI symptoms was recorded by one of the patient's parents/adopter on a diary card twice a day (morning and evening) on Days 1-5.	baseline and days 2, 3, 4 and 5 of observation
Secondary	Severity of the Disease Within 6 Days Was Assessed Using the "Area Under the Curve" for the Total Symptom Score (TSS)	The Total Symptom Score (TSS) was based on the severity of each of acute respiratory infection (ARI) symptom.; The TSS includes 13 symptoms: Body temperature / fever, Non-specific ARI symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), Nasal/Throat/Chest symptoms (Runny nose, Nasal congestion, Sneezing, Sore throat, Hoarseness, Cough, Chest pain/Tightness of the chest).; The severity of Non-specific and Nasal/Throat/Chest symptom was scored on a symptom severity scale (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms). The Fever was scored on a symptom severity scale 0 = no symptom (=37,30?); 1 = mild symptom (37,4-38,00?); 2 = moderate symptom (38,1-39,00); 3 = severe symptom (=39,10?).; Minimum score=0; maximum score=39. The severity of ARI symptoms was recorded: 1) by the doctors on the case record form on Days 1, 3, 6; 2) by one of the patient's parents/adopter on a diary card twice a day (morning and evening) on Days 1-5.	On days 1-6 of observation
Secondary	Number of Intakes of Antipyretics if Indicated	Based on data mentioned in a patient's diary	On day 1, 2, 3, 4 and 5 of the treatment
Secondary	Percentage of Patients With Exacerbation of the Disease Course	The development of disease complications requiring antibiotics administration or hospitalization	On days 1-6 of observation